chromatography

A common misconception is that stronger is always better. However, Nuvia wPrime 2A Media, a weak anion exchange hydrophobic interaction (AEX-HIC) mixed-mode chromatography resin, has won over purification scientists. Read about diverse use cases for Nuvia wPrime 2A Media and see the data for yourself.

Bio-Rad’s Chromatography Support Scientist, Artur Stanczak, discusses the company’s comprehensive downstream process development services. From method development to troubleshooting, Bio-Rad provides specialized support to help customers overcome bioprocessing challenges. Access tools, case studies, and expert guidance to optimize processes and advance biomanufacturing efforts in this informative video.

Although chromatography resins are usually thought of as tools to purify medicines, groundbreaking treatments now utilize resin beads as an integral component of the therapy itself. These therapies are essential for treating certain cancers and inflammatory disorders.

In recent years, gene therapy treatments have increased significantly, requiring more efficient processes to purify and deliver these therapeutics. Lentiviral vectors (LVVs) are a type of retrovirus and are an effective tool for gene delivery. In this webinar, data are shown for a high-throughput screening strategy that was employed for LVV purification, which provided high yield as well as acceptable host cell protein (HCP) clearance.

Nuvia wPrime 2A Resin has MMAEX functionality with a weak anion exchanger. See data showing improved mAb and bsAb purification compared to traditional resins.

Choosing the right chromatography resin is a complex and critical decision that can significantly impact the success of your downstream purification workflow, whether for preparative or analytical applications. To make an informed choice, you must consider the scientific principles of the process, practical implications for your specific application, and attributes of the manufacturer.

Modern chromatographic resins enable new strategies for downstream processing of bispecific antibodies. Watch this webinar to see case studies and workflows.

As biotherapeutic modalities have diversified and production processes become more advanced, an evolution in purification strategies is also needed. Modern biotherapeutic purification must be capable of removing multiple types of impurities without compromising yield or quality, in a cost-effective manner. To meet these needs, many are turning to mixed-mode chromatography.

Large molecule purification presents significant challenges due to their considerable size. For instance, Immunoglobulin M (IgM) molecules, ranging from 900 to 1,000 kD, play pivotal roles in mammalian immune responses and find extensive applications in diagnostics and therapeutics. Purification of such molecules is particularly intricate owing to several factors including their weak Protein A binding sites, limited dynamic binding capacity, and slow diffusion rates.

For over 30 years, CHT Ceramic Hydroxyapatite Chromatography Media has been a trusted, proven purification solution for many biopharmaceutical manufacturing processes. CHT Media provides exceptional removal of impurities when other chromatography resins fall short. In this webcast, explore the essential facts and benefits of this chromatography technology.